Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 193–216 of 235
Longevity risk at the individual level
Longevity extends exposure to health shocks, care disruption, and systemic strain—making it fundamentally a risk-horizon problem rather than a retirement finance problem. European care systems face critical workforce shortages that will compress healthspan and financial security simultaneously, particularly as informal care networks continue to deteriorate.
AI’s role in the next era of longevity biotech
Artificial intelligence is compressing drug discovery timelines from four to five years to approximately fourteen months by automating target identification, molecular design, and clinical trial prediction. This acceleration has direct implications for longevity therapeutics, where speed to market can determine whether interventions reach patients before age-related decline progresses beyond intervention points.
Energy Span reframes fatigue as early warning
Energy Span reframes fatigue as a quantifiable, systems-level signal of healthspan decline that emerges before conventional biomarkers shift into pathological ranges. This perspective bridges the gap between subjective experience and measurable biology, positioning energy as an early warning system reflecting mitochondrial function, metabolic flexibility, circadian rhythm, and autonomic regulation operating in concert.
WHOOP enters $34.5m ARPA-H-backed bid to quantify aging
WHOOP has joined a $34.5 million Stanford-led research initiative to develop the first FDA-grade Intrinsic Capacity score, a predictive model designed to quantify functional healthspan and forecast major health outcomes up to 20 years in advance. The THRIVE coalition integrates continuous wearable physiological data with clinical biomarkers and functional assessments to measure resilience and detect early shifts toward vulnerability before disease manifests.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health, combining epigenetic testing platforms, laboratory infrastructure, and personalized intervention products. The merger positions epigenetic age assessment as a diagnostic tool paired with targeted supplementation and lifestyle recommendations for consumers pursuing longevity optimization.
AI-driven food app targets disease prevention and aging
Foodhak uses AI-driven personalization to translate nutrition science into daily food guidance aligned with individual health markers and goals. The approach positions food as preventive medicine rather than caloric constraint, addressing a systemic gap where most food choices optimize for taste and cost rather than long-term health outcomes.
DEXA standardization essential for longevity tracking
DEXA body composition scanning has moved from clinical obscurity into mainstream longevity medicine, but rapid commercialization has created a quality control problem. Fitnescity Health's Clinical Integrity Standard addresses this by establishing voluntary benchmarks for testing environment stability, quality assurance, and clinical oversight—critical factors for reliable longitudinal tracking.
Biophytis-LynxKite AI alliance broadens longevity drug pipeline
Biophytis and LynxKite are expanding their AI-driven drug discovery partnership beyond sarcopenia to build a broader platform for age-related diseases, including dry age-related macular degeneration. The alliance demonstrates a concrete application of AI to accelerate candidate identification and reduce development timelines in longevity therapeutics.
Why Reactive Medicine Fails Aging Populations
Current healthcare systems spend trillions managing late-life disease reactively through polypharmacy rather than preventing aging-related damage, creating an unsustainable economic crisis that demands a shift toward proactive health maintenance and rejuvenation science. This reallocation is not merely a health matter but an economic imperative tied to GDP growth, retirement security, and workforce productivity.
GARM expands gene therapy platform with Klotho
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Nocturnal Function Reveals Hidden Cardiovascular Decline
Emagene.life and Adam Health have partnered to deliver AI-driven men's health optimization across Southeast Asia, integrating wearable biodata tracking with functional medicine assessment. The collaboration centers on detecting physiological decline through early biomarkers—particularly nocturnal erectile function as a cardiovascular and metabolic health indicator—before symptomatic disease emerges.
Frailty Reversal Reduces Mortality in Aging Populations
Sustained frailty remission—the persistent reversal of frailty status over time—associates with reduced all-cause and cause-specific mortality in aging populations. This finding establishes frailty as a modifiable risk factor with direct implications for mortality reduction, not merely a marker of inevitable decline.
Platform Over Hardware: How Google Health Shifts Wearable Economics
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Klothea initiates longevity-focused human trial of klotho therapy
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
Erectile dysfunction drugs and longevity
PDE5 inhibitors, established drugs for erectile dysfunction, are attracting early interest in longevity medicine for their capacity to improve vascular function and tissue resilience through nitric oxide signaling—not by targeting root causes of aging, but by supporting system performance under the stress of accumulated damage.
Healthspan Gap Widens: Canada's Silent Health Crisis
Healthspan—the years lived in good health—has declined in Canada despite increased longevity, with citizens now facing roughly two decades of chronic disease or cognitive decline. This gap between how long we live and how well we live represents the actual crisis in aging, one addressed far less by research and healthcare spending than lifespan extension.
Organizational Longevity Risk: Three Layers of Demographic Exposure
Enterprises face structural exposure to longevity risk across workforce, customer base, and balance sheet—yet most organizations treat demographic change as peripheral rather than integrating it into core risk governance. This misalignment creates operational, financial, and strategic vulnerability as populations age across developed markets.
WHOOP’s $575m raise backs always-on health
WHOOP has secured $575 million in Series G funding at a $10.1 billion valuation, positioning itself as a continuous health monitoring platform that translates physiological data into actionable guidance. The funding reflects investor confidence that longevity platforms embedding real-time health tracking into daily life can shift healthcare from reactive to proactive intervention.
Evolve Science launches longevity peptide platform
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Longeveron publishes stem cell therapy frailty trial results
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
LifespanningRx launches partner program for peptide therapy
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
João Pedro de Magalhães on the Ethics of Longevity
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
Your Mindset is the Secret to Aging in Reverse
A longitudinal study found that 45% of older adults show cognitive improvement over a decade, with positive age-related beliefs associated with better outcomes. This challenges the assumption that cognitive decline is inevitable with age and suggests mindset-dependent mechanisms may influence cognitive trajectory.